Genmab A/S has stopped development of enapotamab vedotin, an antibody-drug conjugate being investigated for the treatment of solid tumours after early clinical data did not meet the company’s criteria. “While enapotamab vedotin has shown some evidence of clinical activity, this was not optimised by different dose schedules and/or predictive biomarkers,” the company said on 24 November.
